<DOC>
	<DOCNO>NCT02729493</DOCNO>
	<brief_summary>This single-arm , multicenter Phase 2 trial treat patient relapse refractory liver cancer infusion patient 's T cell genetically modify express chimeric antigen receptor ( CAR ) bind tumour cell express EPCAM protein cell surface.The study determine modify T cell help body 's immune system eliminate tumour cells.The trial also study safety treatment CAR-T , long CAR-T cell stay patient 's body impact treatment survival .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety With CAR-T Liver Cancer</brief_title>
	<detailed_description>This single-arm , multicenter Phase 2 study evaluate efficacy safety CAR-T Liver Cancer.The study conduct use phaseⅠ /Ⅱ disign.The study follow sequential phase : Part A ( screen leukapheresis , cell product preparation , cytoreductive chemotherapy ) Part B ( treatment follow-up ) .The follow-up period paticipant approximately 35 month final CAR-T infusion.The total duration study expect approximately 3 years.A total 25 patient may enrol period 3 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . According UICC liver cancer diagnosis treatment guideline diagnosis hepatocellular carcinoma patient , traditional treatment invalid , advance liver cancer , postoperative relapse refractory patient hepatocellular carcinoma , flow cytometry immune tissue ( cell ) chemistry , confirmation tumor cell positive expression relevant molecular target ; 2 . Age &lt; =75 year old , male female ; 3 . Is expect survive 3 month ; 4 . Physical condition good : 02 score ECOG score ; 5 . The lymphocyte count must &gt; =0.4*10^9/L time collection peripheral blood ; 6 . Vital organ ( heart , kidney ) function normal , major wound heal . No serious virus , bacterial infection ; 7 . Non pregnancy lactation ; 8 . History severe allergic reaction without biological product ; 9 . Voluntary participation , good compliance , subject cooperate experimental observation , sign write Informed Consent Form ; 10 . At least one measurable lesion . 1 . Pregnant lactating woman ; 2 . Organ failure , heart : Class III IV ; liver : Chlid grading liver function grade C ; kidney : kidney failure uremia stage ; lung : symptom severe respiratory failure ; brain : disorder consciousness ; 3 . Patients significant graft versus host disease ( GVHD ) organ transplant history allogeneic hematopoietic stem cell transplantation ; 4 . Long term use immunosuppressive drug people severe autoimmune disease ; 5 . Any chronic disease patient treat immune agent hormone therapy ; 6 . A serious infectious disease severe , uncontrollable , wind heal 7 . Allergy interleukin interferon cytokine ; 8 . Coagulation abnormality severe thrombosis ; 9 . Patients participate clinical trial clinical trial past 30 day 10 . The Investigator believe patient participate experiment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liver Cancer CAR-T</keyword>
</DOC>